BriaCell Reports Unprecedented Anti-Tumor Activity If Its Next Generation Personalized Breast And Prostate Cancer Immunotherapies In Tumor Models At The 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS IND
Portfolio Pulse from Benzinga Newsdesk
BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW) (TSX:BCT) has reported unprecedented anti-tumor activity in tumor models by its next generation breast and prostate cancer immunotherapies. The FDA has authorized Bria-OTS™ Investigational New Drug Application (IND), opening the path to the clinic. The company's data shows broad immune system responses to the next generation immunotherapies compared with those of the earlier formulation. The company expects the administration of personalized BRIA-OTS+™ and BRIA-PROS+™ immunotherapies to provide safe and effective treatment options for cancer patients.
November 03, 2023 | 12:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BriaCell's next generation cancer immunotherapies have shown unprecedented anti-tumor activity. The FDA's authorization of Bria-OTS IND opens the path to the clinic, which could potentially boost the company's stock.
The news of BriaCell's next generation cancer immunotherapies showing unprecedented anti-tumor activity is highly relevant and important for the company. The FDA's authorization of Bria-OTS IND opens the path to the clinic, which could potentially boost the company's stock as it indicates progress in the company's product development and potential future revenue. This is likely to be viewed positively by investors, hence the positive score.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100